Voyager Therapeutics (VYGR) Price & Analysis

Compare

1,340 Followers

VYGR Stock Chart & Stats

$3.84

-$0.14(-2.36%)

At close: Jan 08 4:00 PM EST

$3.84

-$0.14(-2.36%)

Day’s Range― - ―

52-Week Range$2.65 - $5.55

Previous CloseN/A

Volume91.62K

Average Volume (3M)555.04K

Market Cap

$229.16M

Enterprise Value$202.44M

Total Cash (Recent Filing)$196.45M

Total Debt (Recent Filing)$36.50M

Price to Earnings (P/E)―

Beta1.31

Next Earnings

May 12, 2026

EPS Estimate

-0.53

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.46

Shares Outstanding59,599,377

10 Day Avg. Volume458,729

30 Day Avg. Volume555,037

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)1.18

Price to Sales (P/S)5.71

P/FCF Ratio-1.71

Enterprise Value/Market Cap0.88

Enterprise Value/Revenue5.01

Enterprise Value/Gross Profit5.57

Enterprise Value/Ebitda-1.62

Forecast

1Y Price Target

$14.67

Price Target Upside282.03% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)-1.82

Revenue Forecast (FY)$54.59M

Bulls Say, Bears Say

Bulls Say

Biomarker ImagingTau PET imaging readouts from the anti-tau antibody program could demonstrate target engagement and measurable tau reduction, providing biological proof of concept that supports program advancement.

Delivery Technology ValidationHuman testing of a partner's gene therapy using the capsid engineered to cross the blood–brain barrier could provide first-in-human validation of the brain delivery platform and increase confidence in its therapeutic reach.

Partnerships And Non-dilutive FundingCollaborations with large biopharma and advancing partnered programs can offer external validation, share development risk, and create opportunities for non-dilutive financing that supports continued development.

Bears Say

Competitive Readout RiskCompeting anti-tau trial results that show tau lowering without symptomatic improvement would call into question whether tau reduction translates into clinical benefit and could negatively affect strategic confidence.

Program Pause And Pipeline ConcentrationPausing the APOE gene therapy program to prioritize resources narrows near-term pipeline diversity and increases reliance on a smaller set of clinical assets.

Trial Design And Clinical Outcome RiskThe tau study is designed to show a biological effect but is not powered to demonstrate clinical benefit, so positive biomarker results may not guarantee improved patient outcomes or commercial viability.

Voyager Therapeutics News

Voyager Therapeutics reports Q4 EPS (46c), consensus (51c)

Reports Q4 revenue $15.34M, consensus $10.49M. “Building on our pipeline progress in 2025, Voyager expects 2026 to be...

15d ago

VYGR

Voyager Therapeutics: Early-Stage Tau Program Optionality Drives High-Risk, High-Upside Buy Rating

Voyager Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Samantha Semenkow from...

11h ago

VYGR

Voyager Therapeutics: Differentiated CNS Platform, Strategic Partnerships, and 2026 Data Catalysts Underpin Buy Rating

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Voyager Therapeutics, retaining the price target of...

7d ago

VYGR

Voyager Therapeutics: Advancing Tau-Targeted Gene Therapy with Multiple Near-Term Catalysts and Attractive Risk-Reward

Analyst Yun Zhong of Wedbush maintained a Buy rating on Voyager Therapeutics, with a price target of $8.00....

13d ago

VYGR

Voyager Therapeutics Faces Rising Tariff and U.S.–China Geopolitical Risks as BIOSECURE Act Threatens Key Chinese CDMO Partnerships

Voyager Therapeutics Inc. (VYGR) has disclosed a new risk, in the Capital Markets category. Voyager Therapeutics Inc. faces...

13d ago

VYGR

Voyager Therapeutics: Undervalued Neurology Pipeline With High-Reward 2026 Catalysts Supports Buy Rating

Voyager Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sumant Kulkarni from...

14d ago

VYGR

Voyager Therapeutics: 2026 Tau Data Catalysts and Gene Therapy Milestones Support Buy/High Risk Rating

In a report released today, Samantha Semenkow from Citi maintained a Buy rating on Voyager Therapeutics, with a...

14d ago

VYGR

VYGR Upcoming Earnings Report: What to Expect?

Voyager Therapeutics Inc. (VYGR) is scheduled to report 4th quarter earnings on 03/10/2026. Regarding Q4 estimates, Wall Street...

16d ago

VYGR

Voyager Therapeutics Announces Chief Medical Officer Resignation

An announcement from Voyager Therapeutics ( ($VYGR) ) is now available. On February 9, 2026, Voyager Therapeutics, Inc....

1M ago

VYGR

Voyager Therapeutics Highlights 2026 CNS Pipeline and Strategy

Voyager Therapeutics ( ($VYGR) ) has issued an update. Voyager Therapeutics has posted a new corporate investor presentation...

2M ago

VYGR

Voyager Therapeutics price target lowered to $25 from $30 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Voyager Therapeutics (VYGR) to $25 from $30 and keeps a...

4M ago

VYGR

Voyager Therapeutics Reports Increased Losses Amid Rising R&D Costs

Voyager Therapeutics Inc. ( ($VYGR) ) has released its Q3 earnings. Here is a breakdown of the information...

4M ago

VYGR

Voyager Therapeutics files $400M mixed securities shelf

16:09 EST Voyager Therapeutics (VYGR) files $400M mixed securities shelf Published first on TheFly – the ultimate source...

4M ago

VYGR

Voyager Therapeutics price target lowered to $11 from $12 at Leerink

Leerink lowered the firm’s price target on Voyager Therapeutics (VYGR) to $11 from $12 and keeps an Outperform...

4M ago

VYGR

VYGR FAQ

What was Voyager Therapeutics’s price range in the past 12 months?

Voyager Therapeutics lowest stock price was $2.65 and its highest was $5.55 in the past 12 months.

What is Voyager Therapeutics’s market cap?

Voyager Therapeutics’s market cap is $229.16M.

When is Voyager Therapeutics’s upcoming earnings report date?

Voyager Therapeutics’s upcoming earnings report date is May 12, 2026 which is in 49 days.

How were Voyager Therapeutics’s earnings last quarter?

Voyager Therapeutics released its earnings results on Mar 09, 2026. The company reported -$0.46 earnings per share for the quarter, beating the consensus estimate of -$0.511 by $0.051.

Is Voyager Therapeutics overvalued?

According to Wall Street analysts Voyager Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Voyager Therapeutics pay dividends?

Voyager Therapeutics does not currently pay dividends.

What is Voyager Therapeutics’s EPS estimate?

Voyager Therapeutics’s EPS estimate is -0.53.

How many shares outstanding does Voyager Therapeutics have?

Voyager Therapeutics has 59,599,377 shares outstanding.

What happened to Voyager Therapeutics’s price movement after its last earnings report?

Voyager Therapeutics reported an EPS of -$0.46 in its last earnings report, beating expectations of -$0.511. Following the earnings report the stock price went up 21.655%.

Which hedge fund is a major shareholder of Voyager Therapeutics?

Currently, no hedge funds are holding shares in VYGR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Voyager Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-48.94%

Trailing 12-Months

Asset Growth

-32.33%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Voyager Therapeutics

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Voyager Therapeutics (VYGR) Earnings & Revenues

Historic Earnings Reports

VYGR Stock 12 Month Forecast

Average Price Target

$14.67

▲(282.03% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","26":"$26","7.25":"$7.25","13.5":"$13.5","19.75":"$19.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,7.25,13.5,19.75,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.15,5.753846153846155,7.357692307692308,8.961538461538462,10.565384615384616,12.16923076923077,13.773076923076923,15.376923076923077,16.980769230769234,18.584615384615386,20.18846153846154,21.792307692307695,23.396153846153844,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.15,4.9592307692307696,5.768461538461539,6.577692307692308,7.386923076923077,8.196153846153846,9.005384615384616,9.814615384615385,10.623846153846154,11.433076923076923,12.242307692307692,13.051538461538462,13.86076923076923,{"y":14.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.15,4.446153846153846,4.742307692307692,5.038461538461538,5.334615384615384,5.63076923076923,5.926923076923077,6.223076923076923,6.519230769230769,6.815384615384615,7.111538461538461,7.407692307692308,7.703846153846154,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.37,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.55,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.58,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.68,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.67,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.95,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.93,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.15,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >